EvaluatePharma World Preview 2018, Outlook to 2024

${downloadButtonText}

Worldwide prescription drug sales accelerate to $1.2 trillion by 2024

Unmet need in the pharmaceutical industry is forecast to drive annual compound growth to over 6%. Take advantage of forward-looking insights that help you maximise the opportunities for growth at your organisation.

Our report also shows that the threat of biosimilars or genericisation for some of the industry’s biggest products could act as a brake on industry growth. $251bn of sales are at risk between 2018 and 2024, teeing up a second patent cliff for the industry.

Key Highlights

  • Prescription drug sales expected to reach $1.2trn in 2024 (+6.4% CAGR 2018-2024)

  • R&D spend is forecast at 16.9% of prescription sales in 2024

  • Oncology continues to be a key industry driver, with a forecasted CAGR of 12% from 2017 to 2024

EvaluatePharma World Preview 2018, Outlook to 2024

Worldwide prescription drug sales accelerate to $1.2 trillion by 2024

Unmet need in the pharmaceutical industry is forecast to drive annual compound growth to over 6%. Take advantage of forward-looking insights that help you maximise the opportunities for growth at your organisation.

Our report also shows that the threat of biosimilars or genericisation for some of the industry’s biggest products could act as a brake on industry growth. $251bn of sales are at risk between 2018 and 2024, teeing up a second patent cliff for the industry.

Key Highlights

  • Prescription drug sales expected to reach $1.2trn in 2024 (+6.4% CAGR 2018-2024)

  • R&D spend is forecast at 16.9% of prescription sales in 2024

  • Oncology continues to be a key industry driver, with a forecasted CAGR of 12% from 2017 to 2024

  • Novartis will be the leading prescription drug company in 2024 with sales of $53.2bn

  • Humira remains the top selling drug in 2024, despite a CAGR of -3% over the next 7 years

Download